Tonix Pharmaceuticals Holding Corp. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; separate fourth-quarter results are not provided. Tonix is a development-stage biopharmaceutical company with two marketed migraine products and a broad clinical and preclinical pipeline.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Net product revenue | $7.8 million | $0 |
| Cost of sales | $4.7 million | $0 |
| Research and development | $86.7 million | $81.9 million |
| General and administrative | $34.8 million | $30.2 million |
| Operating loss | $118.4 million | $112.1 million |
| Other income, net | $1.7 million | $1.9 million |
| Net loss | $116.7 million | $110.2 million |
| Cash used in operating activities | $102.0 million | $98.1 million |
| Cash used in investing activities | $29.1 million | $48.1 million |
| Cash provided by financing activities | $36.5 million | $87.8 million |
- Tonix began recognizing product revenue after acquiring Zembrace SymTouch and Tosymra from Upsher-Smith on June 30, 2023. FY 2023 revenue comprised $6.3 million from Zembrace and $1.5 million from Tosymra. Results include only the post-acquisition period.
- Gross profit on reported product revenue was approximately $3.0 million, or about 39% of revenue, before other operating expenses.
- At year-end, cash and cash equivalents were $24.9 million, working capital was $28.9 million, total assets were $154.5 million, and accumulated deficit was $600.7 million. Cash and cash equivalents were $120.2 million at year-end 2022.
- Debt included an $11.0 million term loan originated in December 2023; its net carrying value was $9.0 million, with $2.4 million classified as current and $6.6 million as long-term. Interest is the greater of prime plus 3.5% or 12%; the loan is secured by the Frederick R&D Center, Massachusetts Advanced Development Center and certain deposit accounts.
- The auditor issued an unmodified opinion on the financial statements but included a going-concern explanatory paragraph. The company reported recurring losses and negative operating cash flows and stated that additional capital is needed.
Material changes and business developments
- Commercial portfolio: The Upsher-Smith acquisition added two FDA-approved migraine medicines and $13.6 million of inventory at year-end. Purchase consideration was approximately $26.5 million, including deferred amounts; the company also assumed sales-based earn-outs and Tosymra royalties.
- Tonmya (TNX-102 SL) for fibromyalgia: The RESILIENT Phase 3 trial met its primary endpoint, with a reported treatment-placebo difference of 0.7 pain-score units (p=0.00005), and all six key secondary endpoints were statistically significant. The earlier RELIEF Phase 3 trial was positive, while RALLY did not meet its primary endpoint. The FDA conditionally accepted Tonmya as the proposed trade name.
- Other clinical results: TNX-102 SL’s PREVAIL Phase 2 Long COVID study missed its primary pain endpoint, though the company reported numerical activity on fatigue and other measures. TNX-1900 missed its chronic-migraine primary endpoint; development for that indication was discontinued. TNX-1500 completed the clinical phase of its Phase 1 study, with topline results expected in 2024.
- Pipeline and facilities: Tonix expects to start a Phase 2 study of TNX-1300 for cocaine intoxication in 2024; TNX-2900 received FDA IND clearance and orphan-drug designation, followed by Rare Pediatric Disease Designation in March 2024. The company engaged CBRE to seek a strategic partner for or buyer of its Massachusetts Advanced Development Center.
- Financing and share count: December 2023 financing generated approximately $30.0 million gross proceeds through common stock and warrants. The 2023 year-end balance sheet included substantial warrant liabilities. A March 2024 public offering closed April 1, raising approximately $3.9 million net, with additional warrants. The authorized common-share ceiling was increased from 160 million to 1 billion in January 2024.
Outlook, risks and unusual items
- Management planned a Type B pre-NDA meeting in the first half of 2024, NDA submission for Tonmya in the second half of 2024, and an FDA decision in the second half of 2025. These are forward-looking targets, not assured outcomes.
- Management said year-end cash and first-quarter 2024 equity proceeds would support operations into the second quarter of 2024, but not beyond. The audited going-concern note states that available cash and first-quarter proceeds will not meet operating and capital requirements through the second quarter. This is a material difference in the filing’s descriptions of runway.
- Tonix has a history of operating losses and expects further losses; it does not expect product revenue to cover expenses in the foreseeable future. Further financing may be required and could involve substantial equity dilution, debt, asset sales or reduced development activity.
- Key risks include regulatory delay or rejection of Tonmya’s NDA; commercialization, pricing and reimbursement uncertainty for the migraine products; clinical and manufacturing setbacks; dependence on third-party and potentially single-source suppliers; intellectual-property challenges; and competition.
- Nasdaq notified the company in October 2023 that it did not meet the $1 minimum bid-price requirement. The stated initial cure deadline was April 15, 2024; delisting risk and potential reverse split remained relevant in the filing.
- Unusual capital structure considerations include warrant exercise and repricing provisions tied to shareholder approval, authorized shares and Nasdaq rules. The filing reports 209.4 million warrants outstanding at December 31, 2023, in addition to 1.4 million options; later financings and warrant amendments add further potential dilution.
- The company reported no legal proceedings believed likely to have a material adverse effect. It reported effective disclosure controls; the auditor was not engaged to attest to internal control over financial reporting.
Most important facts for investors to verify
- Current cash, burn rate and financing runway, including the precise effect of the April 2024 offering and any subsequent capital raises.
- Whether the FDA meeting occurred, whether Tonmya’s NDA was submitted and accepted, and whether the review timetable or required evidence changed.
- Commercial revenue, gross-to-net deductions, product-level sales trends, customer concentration, and the economics of Upsher-Smith earn-outs and Tosymra royalties.
- Fully diluted share count and potential warrant dilution, including exercise-price amendments, shareholder approvals and Nasdaq compliance status.
- Progress, costs and results for TNX-1300, TNX-1500, TNX-2900 and other priority programs, as well as any decision to sell or partner the Advanced Development Center.
- Resolution of the filing’s differing descriptions of whether available resources extend through the second quarter of 2024.